Carl L. Herndon, MD

As the Chief of the Maternal Fetal Medicine (MFM) division and the Hillary Rodham Clinton Professor of Women's Health, Dr. Simpson supports a skilled team of physicians with expertise in maternal medicine, critical-care obstetrics, prenatal pediatrics, high-risk deliveries, and research, offering the best maternal and fetal care in the region. She also serves as a leader at CUIMC's Carmen and John Thain Center for Prenatal Pediatrics, where patients with pregnancies complicated by fetal malformations, genetic syndromes, or multiple gestations receive comprehensive, multidisciplinary care in a state-of-the-art facility. As former Director of CUIMC's Ob/Gyn Ultrasound program, she has assembled an outstanding group of sonographers and physicians to provide the best available sonographic imaging to women with high-risk pregnancies. Dr. Simpson's specialized training in fetal echocardiography complements her expertise in prenatal diagnosis. She performs invasive fetal procedures such as chorionic villus sampling, amniocentesis, fetal blood sampling, and others required in complex cases, including, fetoscopy and laser photocoagulation for twin-twin transfusion syndrome. Dr. Simpson has served on the board of directors for the Society of Maternal Fetal Medicine, and was a recipient of the Leonard Tow Humanism in Medicine Award in 2010.

Dr. Elaine Wan is the Esther Aboodi Associate Professor of Medicine in Cardiology and Cardiac Electrophysiology at Columbia University Medical Center, College of Physicians and Surgeons and attending physician at NewYork-Presbyterian Hospital. She is trained in Internal Medicine, Clinical Cardiology and is an invasive cardiac electrophysiologist. She is the Director of Electrophysiology Research and oversees all electrophysiology clinical trials. She performs implantation of cardiac devices including pacemaker and defibrillators, as well as ablation of arrhythmias. Dr. Wan is a physician-scientist and focuses on development of novel treatments for heart failure, vascular dysfunction and arrhythmias such as atrial fibrillation. She is a translational researcher also interested in development of innovative imaging modalities to improve ablation delivery. Dr. Wan is a graduate of the Massachusetts Institute of Technology. She received her medical degree from Columbia University College of Physicians and Surgeons and completed her fellowship in Cardiovascular Diseases and Clinical Cardiac Electrophysiology at NewYork-Presbyterian/Columbia. Dr. Wan is on the Board of Trustees of the Heart Rhythm Society. She is the Chairperson for the NIH Study Section of Imaging Technology Development. She is also the Chairperson-elect for the American Heart Association Committee on Arrhythmia and Electrophysiology. Dr. Wan is the recipient of numerous national and international awards including NIH R01s, R03, K08, the 2016 American College of Cardiology Young Investigator Award First Place in Molecular Cellular Cardiology, 2016 Young Physician Investigator Award from the American Society of Clinical Investigators, 2016 Cardiostim/Europace Best Young EP Presentation (Nice, France) and the 2008 American Heart Association Women in Cardiology for Clinical Excellence.She is the recipient of several competitive research grants including NIH NHLBI K08 Mentored Career Development Award, NIH NHLBI R03 Small Grant Program and NIH NHLBI R01 to study the use of 3D mitochondrial dysfunction imaging in cardiac arrhythmias. She is also a recipient of the American Heart Association Scientist Development Grant, grant support from the Foundation of Gender Specific Medicine, Columbia University Louis V. Gerstner Jr. Scholars Program, and Columbia University Provost's Grants Program for Junior Faculty who Contribute to the Diversity Goals of the University. She is vice co-chair of the Heart Rhythm Society Digital Health Committee and a member of the American Heart Association Committee on Electrocardiography and Arrhythmias. She has published over 100 manuscripts in high impact journals such as Nature Medicine, Circulation, Science Translational Medicine, Circulation Research, Journal of Clinical Investigation and Journal of American College of Cardiology. She has written 3 book chapters and given invited talks around the world.

Dr. Larisa Geskin is a Professor of Dermatology (in Medicine) at Columbia University Medical Center and Director of the Comprehensive Skin Cancer Center (CSCC) at the Division of Cutaneous Oncology in the Department of Dermatology. She is a world-renowned specialist in the diagnosis and management of cutaneous lymphomas and other cancers of the skin. Her other areas of expertise include melanoma screening, prevention, medical and surgical therapy, and management of high risk for skin cancer populations. Dr. Geskin is using state-of-the-art methods in melanoma screening and surveillance including Mole Mapping (body mapping) and dermoscopy. She was involved in development of novel melanoma detection methods, including MelaFind among others. Dr. Geskin's team aims to provide multidisciplinary care to skin cancer patients, to conduct cutting edge clinical and basic science research, and to train medical students, residents and fellows in the area of cutaneous oncology. Dr. Geskin completed her residency in Dermatology at University of Pittsburgh Medical Center (UPMC), and a two-year fellowship in cutaneous oncology at University of Pittsburgh Cancer Institute (UPCI) with Louis Falo, MD, PhD, Professor and Chairman, Department of Dermatology, UPMC, and with John Kirkwood, MD, Professor and Vice Chairman for Clinical Research, Director of the Melanoma Center at the UPCI. She is a diplomat of the American Academy of Dermatology, member of the Society for Investigative Dermatology, the International Society for Cutaneous Lymphomas, and US Cutaneous Lymphomas Consortium. She authored over 30 peer-reviewed articles in the field of cutaneous oncology. Her research interest focuses on Cutaneous T-cell lymphoma (CTCL) and biomarkers discovery, genetic profiling and regulation, development of immunotherapy for melanoma and lymphoma.